Company: RGBP
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0001641172-25-022884
Chunk: 14

Company: Regen BioPharma Inc
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
,385 15,426,385

On
November 4, 2024 the Company issued 500,000 20,000

On
November 13, 2024 the Company issued 370,084

On
June 10, 2025 the Company issued 10,000,000 50,000

13. RELATED PARTY TRANSACTIONS

The
Company had the following related party transactions:

  Revenue      

On
June 23, 2015 the Company entered into an agreement (“ Agreement”) with Zander Therapeutics, Inc. (“ Zander”) whereby
The Company granted to Zander an exclusive worldwide right and license for the development and commercialization of certain intellectual
property controlled by The Company (“ License IP”) for non-human veterinary therapeutic use for a term of fifteen years. Zander
is under common control with the Company.

Pursuant
to the Agreement, Zander shall pay to The Company one-time, non-refundable, upfront payment of one hundred thousand US dollars ($100,000)
as a license initiation fee which must be paid within 90 days of June 23, 2015 and an annual non-refundable payment of one hundred thousand
US dollars ($100,000) on July 15th, 2016 and each subsequent anniversary of the effective date of the Agreement.

The
abovementioned payments may be made, at Zander’s discretion, in cash or newly issued common stock of Zander.

Pursuant
to the Agreement, Zander shall pay to The Company royalties equal to four percent (4%) of the Net Sales, as such term is defined in the
Agreement, of any Licensed Products, as such term is defined in the Agreement, in a Quarter.

Pursuant
to the Agreement, Zander will pay The Company ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market
value as monetary consideration) received by Zander from sublicensees (excluding royalties from sublicensees based on Net Sales of any
Licensed Products for which The Company receives payment pursuant to the terms and conditions of the Agreement).

Zander
is obligated pay to The Company minimum annual royalties of ten thousand US dollars ($ 10,000 10,000

The
Agreement may be terminated by The Company:

  If                                                                                                                                       
  The                                                                                                                                      
  The                                                                                                                                      

The
Agreement may be terminated by either party in the event of a material breach by the other party.